Marta Gema Solaz-Ruiz, Lorena Azorín Pérez, Carlos Cauto-Picazo, Honorio Barranco-González, Isabel Pascual-Camps, Enrique España-Gregori
{"title":"Toxicity to intravitreal melphalan in a patient with retinoblastoma.","authors":"Marta Gema Solaz-Ruiz, Lorena Azorín Pérez, Carlos Cauto-Picazo, Honorio Barranco-González, Isabel Pascual-Camps, Enrique España-Gregori","doi":"10.22336/rjo.2023.49","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> Description of melphalan's toxicity in retinoblastoma treatment. <b>Methods:</b> Clinical case report. <b>Results:</b> We presented a case of unilateral retinoblastoma with vitreous seeding at diagnosis, in which the use of intravitreal melphalan produced many adverse reactions. <b>Conclusions:</b> Vitreous seedings have been one of the most important challenges in retinoblastoma treatment. Intravitreal melphalan has achieved the regression of vitreous seedings in a large percentage of cases. It is a safe treatment; however, it can produce toxicity, even with the standard dose of 20-30 µg, which has been poorly documented. Exhaustive follow-up of patients is recommended for an early diagnosis of possible adverse effects. <b>Abbreviations:</b> OS = left eye, RI = magnetic resonance imaging, OCT = optical coherence tomography.</p>","PeriodicalId":94355,"journal":{"name":"Romanian journal of ophthalmology","volume":"67 3","pages":"305-308"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591425/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Romanian journal of ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22336/rjo.2023.49","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: Description of melphalan's toxicity in retinoblastoma treatment. Methods: Clinical case report. Results: We presented a case of unilateral retinoblastoma with vitreous seeding at diagnosis, in which the use of intravitreal melphalan produced many adverse reactions. Conclusions: Vitreous seedings have been one of the most important challenges in retinoblastoma treatment. Intravitreal melphalan has achieved the regression of vitreous seedings in a large percentage of cases. It is a safe treatment; however, it can produce toxicity, even with the standard dose of 20-30 µg, which has been poorly documented. Exhaustive follow-up of patients is recommended for an early diagnosis of possible adverse effects. Abbreviations: OS = left eye, RI = magnetic resonance imaging, OCT = optical coherence tomography.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
